85 results about "Peptidase P" patented technology

Provided herein are compounds of formulae (I)-(IX), or pharmaceutically acceptable salts or deuterated forms thereof as defined herein. Also provided herein are pharmaceutical compositions comprising a compound of formula (I)-(IX) or pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of formula (I)-(IX) or pharmaceutically acceptable salt or deuterated form thereof, e.g., in the treatment of a disease that is treatable by administration of a DPP1 inhibitor.

This invention discloses a quantitative detection kit for arginine peptidase, a qualitative detection kit for arginine peptidase, and their usage methods. The quantitative detection kit utilizes the specific substrate Nα-benzoyl-DL-arginine-4-ylbenzamide hydrochloride, which can be hydrolyzed by arginine peptidase to 4-ylbenzamide. 4-ylbenzamide has a maximum absorption peak at 405 nm, and the specific arginine peptidase activity can be rapidly detected at room temperature using spectrophotometry. The qualitative kit utilizes the specific substrate Nα-benzoyl-DL-arginine-β-naphthamide hydrochloride, which can be hydrolyzed by arginine peptidase to p-β-naphthamide. β-naphthamide combines with 4-(dimethylamino)cinnamaldehyde to form a compound that is visible to the naked eye as a pink color. The disulfide bond cleaving agent cuts the mucus disulfide bonds, exposing bacterial enzyme sites, and the synergistic effect of the enzyme activator enhances the reaction rate of arginine peptidase hydrolysis of the substrate, significantly improving the detection sensitivity of arginine peptidase in tongue coating samples.

Provided herein are compounds of Formulae (I), (II), (III), and (III-d). Also provided herein are methods of preparation of Formulae (I), (II), and (III-d). Further provided herein are methods of functionalizing or sequencing a peptide by reaction of compounds of Formula (III-d) with peptidases.

The invention discloses a polypeptide as well as preparation and application thereof, and belongs to the technical field of active peptides. According to the present invention, three active peptides are prepared from walnut meal protein, the amino acid sequences of the three polypeptides are respectively Leuu-Pro-Gln-Phe (LPQF), Leuu-Pro-Ser-Phe (LPSF) or Vla-Pro-Phe-Pro (VPFP), and the detection results show that the three polypeptides have inhibition activity on dipeptidyl peptidase-IV (DPP-IV), such that the three polypeptides can be used for preparing the blood sugar reducing drug.

The application belongs to the technical field of biotechnology, and particularly relates to application of albumin polypeptide gel beads in a product for treating or preventing sarcopenia. Egg white protein is used as raw material to extract protein, and albumin dipeptide-based peptidase-IV inhibitory peptide is prepared through a biological enzymolysis method. Bioinformatics analysis is used to screen out the inhibitory peptide TPYMFP, and the IC50 value of the inhibitory peptide TPYMFP for dipeptide-based peptidase-IV reaches 3.12 ± 0.49 mmol / L. Further, the optimal preparation conditions of sodium alginate SA and carboxymethyl chitosan CMCS-based gel beads CMCS / SA / TPYMFP are explored. When the SA concentration is 1.5% (w / v), the CMCS concentration is 0.5% (w / v), and the CaCl2 concentration is 1% (w / v), the polypeptide encapsulation rate is increased to 98.26% ± 0.25%. It is verified that the albumin polypeptide gel beads have good pH response characteristics, and efficient protection and intestinal target delivery of the sarcopenia inhibitory peptide are realized. The albumin polypeptide gel beads are applied to preparation of a product for treating or preventing sarcopenia, or in preparation of a related product for increasing muscle mass and strength.

The present invention relates to the dipeptidyl-peptidase I (DPPI or Cathepsin C) inhibitor of formula (I), which is useful in the prevention and / or treatment of bronchiectasis with certain underlying aetiologies, in the prevention and / or treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis or hidradenitis suppurativa using therapeutically efficacious dosages and to polymorphs of Compound (I) as well as to pharmaceutical compositions comprising Compound (I) and its polymorphs.

The invention relates to a pharmaceutical composition for reducing dentin hypersensitivity and a preparation method thereof, and belongs to the technical field of biological medicine, the pharmaceutical composition comprises chanterelle extract, rabdosia rubescens leaf extract, eggshell membrane protein peptide and bifidobacterium thermophile fermentation extract; the cantharellus cibarius extract is obtained by sequentially performing enzymolysis on cantharellus cibarius through compound enzyme, ginger protease and serratipeptidase and purifying enzymatic hydrolysate through an AB-8 macroporous resin column. The rabdosia rubescens leaf extract is obtained by ultrasonically extracting rabdosia rubescens leaves with an ethanol water solution and purifying an extracting solution with a composite filler adsorption column. The eggshell membrane protein peptide is obtained by carrying out enzymolysis on a shell membrane by virtue of ginger protease and ficin and purifying an enzymatic hydrolysate by virtue of a G-25 sephadex column. The fermentation extract of the bifidobacterium thermophilus is obtained by purifying fermentation liquor of the bifidobacterium thermophilus through an SP agarose gel FF column. All the components are compounded according to a specific ratio and have a synergistic effect, so that the dentin hypersensitivity can be relieved safely in a multi-effect manner.

Provided are fusion proteins that inactivate coronaviruses and uses thereof. The fusion proteins herein comprise an ACE2 peptidase domain comprising the amino acid sequence set forth in SEQ ID NO: 1 directly or via a linker connected to a coronavirus polypeptide therapeutic that targets the HR1 domain. The fusion proteins are broad-spectrum, highly potent, and can inactivate viruses at an early, free stage.

The application discloses a method and application of knocking down ubiquitin-specific peptidase 7 protein, and belongs to the field of biological medicine. The method for knocking down the USP7 protein comprises: specifically inhibiting the expression of USP7 in endothelial cells through gene intervention, and the gene intervention means comprises shRNA, siRNA or recombinant virus carrier-mediated USP7 expression down-regulation. Further provided is a USP7 knockdown reagent for preparing a drug for treating endothelial cell inflammation or a cardiovascular disease, in particular, the USP7 knockdown reagent is a USP7 knockdown virus carrier containing a Cdh5 promoter; the cardiovascular disease comprises heart failure, myocardial infarction or ischemic cardiomyopathy. The application specifically knocks down the expression of USP7 in endothelial cells through gene intervention, significantly improves the migration, tube formation capacity and reduces the apoptosis of the endothelial cells, repairs endothelial dysfunction, the USP7 knockdown virus carrier is used for preparing a drug for treating a cardiovascular disease, and has important clinical value.

This invention provides a fermented extract of Rehmannia glutinosa, a composition thereof, its preparation method, and its application, belonging to the field of biomedical technology. This invention obtains fermented extracts of black tea and Rehmannia glutinosa by fermenting black tea and Rehmannia glutinosa with a single strain of *Aspergillus cristatus*. Experiments have verified that both extracts, used alone, have good inhibitory effects on dipeptidyl peptidase-4. Further, combining the two extracts and verifying through animal experiments, shows that they have good inhibitory activity against dipeptidyl peptidase-4 in the intestine and feces, while also exhibiting a hypoglycemic effect.

Disclosed are a crystal of the compound (S)-N-((S)-1-cyano-2-(2-fluoro-4-(3-methyl-2-oxo-2,3-dihydrobenzo[d]oxazol-5-yl)phenyl)ethyl)-1,4-oxazacycloheptane-2-carboxamide salt or a salt thereof, a preparation method therefor, and the uses thereof in pharmaceutical compositions and in medicine.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a ubiquitin specific peptidase 13 inhibitor in preparation of a medicine for treating chronic kidney diseases. According to the present invention, as the acknowledged ubiquitin specific peptidase 13 inhibitor, the results of the in vivo unilateral ureteral ligation animal experiment and the in vitro TGF-beta 1 induced cell experiment show that the Spautin-1 can be used as the ubiquitin specific peptidase 13 inhibitor, the Spautin-1 can be used for alleviating UUO induced renal interstitial fibrosis, alleviating in-vitro TGF-beta1 induced renal fibroblast activation and regulating and controlling the cell cycle process of the TGF-beta1 induced renal fibroblast. The Spautin-1 has the advantages that the UUO induced renal interstitial fibrosis can be alleviated, and the in-vitro TGF-beta1 induced renal fibroblast activation can be alleviated; therefore, the Spautin-1 can relieve the CKD-related diseases and can be used for preparing the medicine for treating the CKD and the related diseases. The invention provides a new medicine source for relieving and treating CKD, and has a good clinical application prospect.

Materials, methods, and systems for enhanced protease targeting. For example, methods for the targeting of kallikrein related peptidase 2 (KLK2) are provided.

The invention relates to the technical field of biological medicines, in particular to application of dipeptidyl peptidase 3 (DPP3) as a treatment target of septicopyemia-induced myocardial injury. The invention discloses a key action mechanism of dipeptidyl peptidase 3 (DPP3) in septicopyemia induced myocardial injury, and provides a novel septicopyemia cardiomyopathy intervention strategy taking DPP3 as a target spot based on the key action mechanism. A theoretical basis and an experimental basis are provided for developing early diagnosis tools and targeted therapy drugs for septicopyemia-induced cardiomyopathy, and remarkable clinical application value and significance are achieved.

A method for treating cancer is provided. The method includes administering a combination of a Prolidase, also known as peptidase D (PEPD), in combination with a monoclonal antibody or antigen binding fragment thereof that binds with specificity to a clotting factor, such as Factor XII (FXII). A single dose of the monoclonal antibody is sufficient to enable a therapeutic effect of the PEPD.

The present disclosure relates to certain (2S)—N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof),that inhibit dipeptidyl peptidase 1 (DPP1) activity, to their utility in treating and / or preventing clinical conditions including respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD), to their use in therapy, to pharmaceutical compositions containing them and to processes for preparing such compounds.

To find out a novel component having dipeptidyl peptidase-IV inhibitory activity, and provide a dipeptidyl peptidase-IV inhibitor, a hyperglycemia inhibitor and an anti-diabetic agent.SOLUTION: Tetrapeptide Ile-Pro-Ala-Gly and tripeptide Val-Ala-Tyr included in hydrolysate of almond-derived protein has dipeptidyl peptidase-IV inhibitory activity, and can be used as a dipeptidyl peptidase-IV inhibitor, a hyperglycemia inhibitor and an anti-diabetic agent.SELECTED DRAWING: None

The invention discloses a multifunctional bioactive peptide from highland barley and application of the multifunctional bioactive peptide. The bioactive peptide has an amino acid sequence as shown in SEQ ID NO: 1. The multifunctional bioactive peptide disclosed by the invention has the activity of inhibiting angiotensin converting enzyme, the activity of inhibiting dipeptidyl peptidase-4, the antioxidant activity and the anti-inflammatory activity, can be used for developing polypeptide medicines or functional foods with a disease treatment effect, and has a good application prospect.

The present disclosure provides antibodies and polypeptides that specifically bind to kallikrein related peptidase 6 (KLK6). Also provided are compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

The invention discloses a method for enhancing the synthetic ability of yeast total protein and dipeptide tripeptide. Relates to the technical field of synthetic biology and metabolic engineering. According to the invention, the saccharomyces cerevisiae engineering strain with high protein synthesis capability and high endogenous dipeptide and tripeptide accumulation level is successfully constructed. The metabonomics analysis reveals the unique peptide fragment accumulation spectrum, especially the generation of a large amount of lysine-rich tripeptide at the C terminal, and proposes a potential mechanism of metabolic pathway'bottleneck 'caused by peptidase activity down-regulation in combination with proteome data. The recombinant strain has important application potential in the fields of single-cell protein, functional peptide products and the like.

The invention discloses a polypeptide as well as preparation and application thereof, and belongs to the technical field of active peptides. According to the present invention, three active peptides are prepared from walnut meal protein, the amino acid sequences of the three polypeptides are respectively Leuu-Pro-Gln-Phe (LPQF), Leuu-Pro-Ser-Phe (LPSF) or Vla-Pro-Phe-Pro (VPFP), and the detection results show that the three polypeptides have inhibition activity on dipeptidyl peptidase-IV (DPP-IV), such that the three polypeptides can be used for preparing the blood sugar reducing drug.

The object of the invention is a recombinant protein with antibacterial properties having an amino acid sequence derived from the sequence of the M23 domain from Streptococcus thermophilus of a peptidoglycan hydrolase character, preferably in the form of a recombinant protein chimera, as well as compositions comprising it, their uses and methods utilizing thereof. The invention is based on recombinant proteins being peptidoglycan hydrolases with peptidase properties - derived from the M23 domain originating from Streptococcus thermophilus, showing a particularly high specificity to Gram (+) bacteria with a direct cross-linking bridges in peptidoglycan, and discloses the proteins of a recombinant protein chimera such as LB24, additionally comprising a bacteria cell wall binding CWT domain from Staphylococcus pettenkoferi.

This disclosure provides modified AAV vectors for expressing tripeptidyl peptidase 1 (TPP1) in objects. Some aspects of this disclosure provide modified adeno-associated virus 1 (AAV1) vectors comprising a capsid protein containing a targeting peptide and a nucleic acid molecule containing a sequence encoding a modified AAV genome, said modified AAV genome comprising a replication (rep) gene, a capsid (cap) gene, and a tripeptidyl peptidase 1 (TPP1) transgene.

The invention belongs to the field of biological pharmacy, and relates to a dipeptidyl peptidase IV inhibitory oligopeptide and application thereof. Specifically, the DPP-IV inhibitory peptide is designed by computer-aided design. The polypeptide with DPP-IV inhibitory activity is screened out through virtual amino acid mutation, online database prediction, molecular docking and other methods. The invention proves that the LAFPGSW polypeptide can obviously improve the physiological indexes of diabetic mice, has no toxic or side effect, and can relieve the change of mouse liver weight and mouse body weight caused by diabetes, so that the mouse liver weight and the mouse body weight are recovered to a normal level; according to the present invention, the compound can significantly reduce the levels of AST, ALT, TC and TG in serum, and relieve LDL-C and HDL-C abnormality, such that the compound has effects of blood sugar lowering, lipid lowering, insulin secretion promoting, insulin resistance improving and the like, and can be used for prevention and treatment of diabetes and diabetic complications.

Provided herein are compounds of Formula (I) or pharmaceutically acceptable salts or deuterated forms thereof, wherein ring A, R 1 、 R 2 、 R 3 、 R 4 、 and m are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt or deuterated form thereof, and methods of using a compound of Formula (I) or a pharmaceutically acceptable salt or deuterated form thereof, for example, in the treatment of a disease that can be treated by administration of a DPP1 inhibitor.(I)

The present invention relates to tricyclic compounds comprising a diazepinone moiety that effectively inhibit Sppl2a (signal peptide peptidase-like protease 2a), pharmaceutical compositions containing such inhibitors, and methods of using such inhibitors and compositions.

The present application relates to a dipeptidyl peptidase I (DPP-1) inhibitor and use, including a compound and a pharmaceutical composition thereof, a preparation method of the compound and a use of the compound in preparation of a drug for preventing and / or treating indications related to DPP-1 signal pathway.

The present invention relates to the dipeptidyl-peptidase I (DPPI or Cathepsin C) inhibitor of formula (I), which is useful in the prevention and / or treatment of bronchiectasis with certain underlying aetiologies, in the prevention and / or treatment of anti-neutrophil cytoplasmic anti- body-associated vasculitis or hidradenitis suppurativa using therapeutically efficacious dosages and to polymorphs of Compound (I) as well as to pharmaceutical compositions comprising Compound (I) and its polymorphs.

The invention relates to a method for the prediction of an increase of dipeptidyl peptidase 3 (DPP3) in a critically ill patient. In particular, the method comprises providing a sample from said patient, determining a level of Dipeptidyl peptidase 3 (DPP3) in said sample, comparing said level to a pre-determined threshold, wherein the level of DPP3 in said sample is indicative of an increase of DPP3 if said level of DPP3 is above a pre-determined threshold level, which is in the range between 22 and 40 ng / ml. Furthermore, the invention also relates to a method for the prevention of a DPP3 increase in a critical ill patient, wherein a DPP3 inhibitor is administered to the patient if the level of DPP3 is above a threshold between 40 ng / ml and 22 ng / ml and said DPP3 inhibitor is an anti-DPP3-antibody and / or and anti-DPP3-antibody fragment and / or anti-DPP3 scaffold. Moreover, the invention also relates to a DPP3 inhibitor for use in the prevention of a DPP3 increase in a critical ill patient.